Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sigmar Italia is an Italian Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of food supplements and medical devices. Based in Almè, the company provides end-to-end services including formulation, manufacturing, and packaging for oral solid and liquid dosage forms. In 2021, Sigmar Italia was acquired by Labomar, a major international nutraceutical group, to enhance its production capabilities and market reach. The company maintains high quality standards with certifications such as GMP and ISO, serving a diverse range of clients in the healthcare and wellness sectors. Its expertise spans across various delivery systems, including tablets, capsules, powders, and syrups. Sigmar Italia is recognized for its innovation in the nutraceutical space and its ability to handle complex product requirements.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sigmar Italia.